TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05694520

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pistachios consumption of 1.5 oz thrice per week
Description: According to the Chinese nutritional guidelines for GDM women, the energy intake of 1500-1800 kcal/d will be recommended for all the included participants with pregestational BMI≥24 kg/m2. Standard care and a balanced diet will be recommended to the women in CG incorporating the total nuts intake of less than 2.5 oz per week). While the women in the IG will be offered the otherwise same diet as their counterparts in the CG, except for the extra intake of pistachios of 1.5 oz thrice per week.
Study: NCT05011682

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Regular diet
Description: participant's usual diet during 2 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 10-point nutrition plan
Description: controlled portions of low glycemic index carbohydrates, avoidance of rapidly absorbed carbohydrates, adjustment of timing of meals and snacks, and attention to personal and cultural barriers to implementation
Study: NCT05042518

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experiment
Description: breathing control and self-talk with objectives

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: The participant in the control group will receive consultations by a sport psychologist for goal setting and positive thinking. The duration is similar to the training group (4-5 minutes in each session, 4 sessions per week for 1 month)
Study: NCT05683587

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ballet course, strength course
Description: Include of two phase,first phase is strength course for three months and second phase is ballet course for three months.
Study: NCT05553704

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: metformin group will take mesalamine 1 gm three times daily plus metformin 500 mg two times daily
Study: NCT05326425

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lazertinib(YH25448)
Description: - lazertinib 240mg(3tablets, 80mg/1tablet), once a day, oral, before disease progression
Study: NCT06330168

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupivacaine-calcitonin-fentanyl
Description: pre-induction single shot thoracic paravertebral block using 20 mL 0.25% bupivacaine, 100 micrograms of fentanyl (2ml), and 100 IU of calcitonin (1ml).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivacaine-fentanyl
Description: pre-induction single shot thoracic paravertebral block using 20 mL 0.25% bupivacaine, 100 micrograms of fentanyl (2ml), and 1 ml saline 0.9%.
Study: NCT06466863

Intervention type: OTHER
Intervention: Validity and Reliability
Description: Participants were included in the study after obtaining consent from both the participants and their parents. Participants were informed about the study prior to the survey, and only those who volunteered were included in the study. The data collection process was conducted online via Google Forms. The assessment form was sent to the participants through social media platforms, messages, and emails. Participants completed the YAP-T twice, 7 days apart, and all measurements were taken on weekdays under similar conditions by the same evaluators (4 evaluators) in the same region (Istanbul).~Test-retest reliability will be determined by calculating the Intraclass Correlation Coefficient (ICC) between the total scores obtained from the two assessments.
Study: NCT06091761

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Auricular acupuncture
Description: Auricular acupuncture is conducted weekly in eight weeks using patches, each with a square shape and a side length of 10 mm, along with sterilized needles measuring 0.25 x 1.3 mm. Five acupoints on one ear are selected, which included Shen-men (TF4), Stomach (CO4), Spleen (CO13), Endocrine (CO18), and Hunger point. The patch with the needle will remain in place for one week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Auricular acupuncture
Description: Auricular acupuncture is conducted weekly in eight weeks using patches, each with a square shape and a side length of 10 mm, along with sterilized needles measuring 0.25 x 1.3 mm. Five acupoints on one ear are selected, which included Shen-men (TF4), Stomach (CO4), Spleen (CO13), Endocrine (CO18), and Hunger point. The patch with the needle will remain in place for one week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thread embedding acupuncture
Description: Thread embedding acupuncture is performed every two weeks in eight weeks using a single Polydioxaone thread. Needles has a gauge size of 29G, a shaft length of 38mm, and a thread length of 50mm, folded in half, and are applied to ten acupoints, including Qihai (CV6), Shuifen (CV9), and Tianshu (ST25), Shuidao (ST28), Daheng (SP15), Siman (KI14) on both sides of the body. Needles with a gauge size of 30G, a shaft length of 25mm, and a thread length of 30mm, folded in half, are used for five acupoints, which included Zhongwan (CV12) and Zusanli (ST36), Pishu (BL20) on both sides of the body. After the thread being inserted into the body, the needle will be withdrawn immediately.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Thread embedding acupuncture
Description: Sham Thread embedding acupuncture is performed every two weeks in eight weeks. Needles without threads has a gauge size of 29G, and a shaft length of 38mm, are applied to ten acupoints, including Qihai (CV6), Shuifen (CV9), and Tianshu (ST25), Shuidao (ST28), Daheng (SP15), Siman (KI14) on both sides of the body. Needles without threads with a gauge size of 30G, and a shaft length of 25mm, are used for five acupoints, which included Zhongwan (CV12) and Zusanli (ST36), Pishu (BL20) on both sides of the body. After the needle being inserted into the body, it will be withdrawn immediately.
Study: NCT06313073

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Neoadjuvant radiotherapy
Description: The patient received synchronous radiotherapy and chemotherapy before surgery. CTV : 40Gy/15fx/3w, sequential GTV： 8.7-10Gy/3-4 Fx.CTV : 40Gy/15fx/3w, sequential GTV： 8.7-10Gy/3-4 Fx.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: adjuvant radiotherapy
Description: The patient received radiotherapy after surgery. CTV : 40Gy/15fx/3w, sequential GTV： 8.7-10Gy/3-4 Fx.CTV : 40Gy/15fx/3w, sequential GTV： 8.7-10Gy/3-4 Fx.
Study: NCT06312904

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: paravertebral block
Description: After cardiac surgery, the anesthesiologist will use 3mg/kg of 0.375% ropivacaine to conduct paravertebral block.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Local infiltration anesthesia
Description: After cardiac surgery, the anesthesiologist will use 3mg/kg of 0.375% ropivacaine to conduct local infiltration anesthesia.
Study: NCT05706012

Intervention type: OTHER
Intervention: Survey
Description: Online survey questioning the current clinical practice on long-term antithrombotic management of AMI in SBS patients
Study: NCT04803799

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training Programme
Description: Cognitive-motor dual task exercises corresponding to associations between different motor tasks and different cognitive tasks.
Study: NCT05192798

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albumin-Bound Paclitaxel
Description: Albumin-bound paclitaxel is one of the standard first-line regimens for relapsed or metastatic triple-negative breast cancer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin-Bound Paclitaxel
Description: Albumin-bound paclitaxel is one of the standard first-line regimens for relapsed or metastatic triple-negative breast cancer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin-Bound Paclitaxel
Description: Albumin-bound paclitaxel is one of the standard first-line regimens for relapsed or metastatic triple-negative breast cancer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib Mesylate
Description: Apatinib mesylate is an orally administered small-molecule vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor (TKI).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab is a humanized anti-VEGF monoclonal antibody once approved by FDA for treatment of metastatic breast cancer in combination with chemotherapy.
Study: NCT05564871

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: occupation-based teleintervention
Description: Intervention protocol will include 12 weekly based on the principles of the CO-OP approach. The intervention will focus on solving problems in the participant's daily life and implementing strategies in accordance with the goals set according to the COPM (Law et al., 2017). In the research group, the intervention will be carried out through videoconference sessions between an occupational therapist located at one of the child development units and the participant and their parents who are at home. The control group will receive a weekly session of CO-OP intervention in-person in one of the child development units.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: occupation-based teleintervention
Description: Intervention protocol will include 12 weekly based on the principles of the CO-OP approach. The intervention will focus on solving problems in the participant's daily life and implementing strategies in accordance with the goals set according to the COPM (Law et al., 2017). In the research group, the intervention will be carried out through videoconference sessions between an occupational therapist located at one of the child development units and the participant and their parents who are at home. The control group will receive a weekly session of CO-OP intervention in-person in one of the child development units.
Study: NCT06175546

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Compression socks
Description: Wearing of compression sock in prescribed regimen

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Compression socks
Description: Wearing of compression sock in prescribed regimen
Study: NCT06111482

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intense pulsed light.
Description: The intense pulsed light (IPL) will be used for treating unwanted dermatologic conditions which may be on multiple areas of the body such as, but not limited to, the face, décolletage, back, legs, arms, and hands.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intense pulsed light.
Description: The intense pulsed light (IPL) will be used for treating unwanted dermatologic conditions which may be on multiple areas of the body such as, but not limited to, the face, décolletage, back, legs, arms, and hands.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiofrequency microneedling device
Description: The microneedling device will be used for treating unwanted dermatologic conditions which may be on multiple areas of the body such as, but not limited to, the face, décolletage, back, legs, arms, and hands.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiofrequency microneedling device
Description: The microneedling device will be used for treating unwanted dermatologic conditions which may be on multiple areas of the body such as, but not limited to, the face, décolletage, back, legs, arms, and hands.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiofrequency device
Description: The radio frequency device will be used for treating unwanted dermatologic conditions which may be on multiple areas of the body such as, but not limited to, the face, décolletage, back, legs, arms, and hands.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiofrequency device
Description: The radio frequency device will be used for treating unwanted dermatologic conditions which may be on multiple areas of the body such as, but not limited to, the face, décolletage, back, legs, arms, and hands.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Combined energy devices
Description: The combined energy devices will be used for treating unwanted dermatologic conditions which may be on multiple areas of the body such as, but not limited to, the face, décolletage, back, legs, arms, and hands.
Study: NCT04107883

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: fresh frozen plasma
Description: perform plasma transfusion in different phases during perioperation

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: blood sample
Description: get blood samples at several specific points in time during perioperation

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: blood sample
Description: get blood samples at several specific points in time during perioperation
Study: NCT04858906

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: McGrath laryngoscope
Description: The patients in this group will be evaluated and intubated with McGrath laryngoscope (angulated videolaryngoscope).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: McGrath laryngoscope
Description: The patients in this group will be evaluated and intubated with McGrath laryngoscope (angulated videolaryngoscope).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: C-MAC D-blade laryngoscope
Description: The patients in this group will be evaluated and intubated with C-MAC D-blade laryngoscope (hyperangulated videolaryngoscope).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: C-MAC D-blade laryngoscope
Description: The patients in this group will be evaluated and intubated with C-MAC D-blade laryngoscope (hyperangulated videolaryngoscope).
Study: NCT05295095

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: positive pressure during extubation procedure
Description: positive pressure during extubation procedure
Study: NCT05019157

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation group
Description: Participants will undertake the first three training sessions in the outpatient clinic for familiarization with the training modalities, the wearable sensors and the data uploading. Afterwards, the participants will proceed with the telerehabilitation program at their homes. The participants will be lent the wearable sensors and will undergo an exercise - based program 3 times/week, comprising of 10' warm up exercises, 40' aerobic, resistance, balance exercises and 10' cool down.Training sessions will be monitored, in real time, by the study investigator. Participants should upload the recorded data to Polar Flow web platform after every training session and should visit the outpatient clinic every month to upload the accelerometry's recorded data to a secure personal computer) application. Educational and informational videoconferences will be held every week for upright training exercise sessions, physical activity counseling, diet/nutritional and smoking cessation counseling.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Centre - based rehabilitation group
Description: Participants will attend an exercise - based cardiac rehabilitation program at the outpatient clinic's facilities under the supervision of cardiac rehabilitation specialized staff. The participants will receive an individually tailored training program on a treadmill or a cycle ergometer. Total training attendance rate will be documented by the cardiac rehabilitation centre staff. Patients will be instructed to wear a tri - axial accelerometer during the entire 12 weeks study period. Participants should upload recorded data to the local server every month. Educational videoconferences will be held every week for physical activity counseling, diet/nutritional and smoking cessation counseling.
Study: NCT05804279

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPDO-1603
Description: donepezil/mematine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BPDO-1603
Description: donepezil/mematine
Study: NCT05551585

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial pulse stimulation
Description: TPS will be performed in three treatment sessions per week, applying 1000 pulses per session (single ultrashort (3 μs) ultrasound pulses, 0.2-0.25 mJ mm-2, \~5 Hz pulse frequency,

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial pulse stimulation
Description: TPS will be performed in three treatment sessions per week, applying 1000 pulses per session (single ultrashort (3 μs) ultrasound pulses, 0.2-0.25 mJ mm-2, \~5 Hz pulse frequency,
Study: NCT05686187

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AR's platform for gender empowerment
Description: The intervention of the experimental group is to accept the courses of the gender empowerment platform introduced by AR. The preliminary plan is 50-60 minutes each time. The content of the teaching plan course will adopt the course module design. Group content, and among the three module courses, there must be a core module course unit that is the workplace sexual harassment prevention unit
Study: NCT05933187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A: Emraclidine 30mg IR tablets (reference)
Description: IR oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A: Emraclidine 30mg IR tablets (reference)
Description: IR oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A: Emraclidine 30mg IR tablets (reference)
Description: IR oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A: Emraclidine 30mg IR tablets (reference)
Description: IR oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B: Emraclidine 30mg IR test tablets 1
Description: IR oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B: Emraclidine 30mg IR test tablets 1
Description: IR oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B: Emraclidine 30mg IR test tablets 1
Description: IR oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B: Emraclidine 30mg IR test tablets 1
Description: IR oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C: Emraclidine 30mg IR test tablets 2
Description: IR oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C: Emraclidine 30mg IR test tablets 2
Description: IR oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C: Emraclidine 30mg IR test tablets 2
Description: IR oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C: Emraclidine 30mg IR test tablets 2
Description: IR oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment D: Emraclidine 30mg IR test tablets 3
Description: IR oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment D: Emraclidine 30mg IR test tablets 3
Description: IR oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment D: Emraclidine 30mg IR test tablets 3
Description: IR oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment D: Emraclidine 30mg IR test tablets 3
Description: IR oral tablets
Study: NCT06418854

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: Adapted design questionnaire to estimate the vaccine hesitancy specifically for dengue vaccine
Study: NCT06243471

Intervention type: PROCEDURE
Intervention: Minimally invasive procedures for the Hallux Abductus Valgus.
Description: Minimally invasive procedures for the Hallux Abductus Valgus

Intervention type: PROCEDURE
Intervention: Minimally invasive procedures for the Hallux Abductus Valgus and a zig-zag tenotomy for the extensus hallux longus.
Description: Minimally invasive procedures for the Hallux Abductus Valgus and a zig-zag tenotomy for the extensus hallux longus.
Study: NCT05638893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Tablet
Description: Placebo (tablet/12hr) + celecoxib (200mg/day) for three months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Hcl 500Mg Tab
Description: Metformin (500mg/12hr) + celecoxib (200mg/day) for three months.
Study: NCT05296525

Intervention type: DRUG
Group type: OTHER
Intervention: GDA-201
Description: NAM-expanded allogeneic NK cells
Study: NCT05606887

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wearable Device and Ecological Momentary Assessments
Description: The intervention will consist of three components:~1. Completion of brief text-message based surveys 2-3 times per week~2. Wearing a wrist-based wearable device to generate individual data insights on physiological data related to stress and well-being, including heart rate variability, stress scores, and sleep quality~3. Individual biweekly reports of survey response trends and curated resources intended to support participant well-being
Study: NCT04898413

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group-based acceptance and commitment therapy (ACT)
Description: Group-based ACT intervention by professional psychotherapist consists of four modules: (a) psychoeducation about dementia and experiential avoidance in caregiving, (b)mindfulness and acceptance of aversive emotions, sensations, and thoughts, (c) behavior management for care recipients' BPSD, and (d) clarifying and choosing one's value, and taking actions toward the chosen values. Each session lasts about 90 minutes and will be held every two weeks. Group-based reminiscence therapy for care recipients will be conducted by a professional psychotherapist other than the one conducting group-based ACT intervention.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group-based cognitive behavioral therapy (CBT)
Description: Group-based CBT intervention by professional psychotherapist consists of four modules: (a) psychoeducation about dementia and distress in caregiving, (b) cognitive restructuring and relaxation, (c) behavior management for care recipients' BPSD, and (d) increasing pleasant activities. Each session lasts about 90 minutes and will be held every two weeks. Group-based reminiscence therapy for care recipients will be conducted by a professional psychotherapist other than the one conducting group-based CBT intervention.
Study: NCT05033808

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: Epirubicin is given once over 15 Minutes via a central line

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: Epirubicin is given once over 15 Minutes via a central line

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: Epirubicin is given once over 15 Minutes via a central line

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: NaCl is given once over 15 Minutes via a central line
Study: NCT05185544

Intervention type: OTHER
Intervention: Neoadjuvant pemetrexed and cisplatin chemotherapy
Description: neoadjuvant pemetrexed and cisplatin chemotherapy in patients with lung adenocarcinoma